Taken together, analyses identified a new mechanism for IGF1R and AR stimulation of prostate cancer, and further support the relevance of targeting AR and IGF1R in this type of tumors with BRCA1 serving as a marker for defining the target activity. The gene discussed is AR; the disease is prostate cancer.